After months of speculation about a rumored sale of its semiconductor unit, Agilent Technologies said this week that it would sell the segment to private equity firms Kohlberg Kravis Roberts and Silver Lake Partners for $2.66 billion.

By shedding a laggard that has been a drag on profitability, Agilent has enabled itself to focus more on growing its Life Sciences and Chemical Analysis group, which will be renamed the Bio-Analytical Measurement business. That segment has been one of the firm's more predictable and profitable businesses.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.